ERBB2 and neoplasm: Taken together, the results of these therapeutic studies, coupled with histological, metabolic, and hematological parameters, suggest that surface conjugation of the SG4015 toxin and anti-HER2 scFv to C′ dots with a DPR = 40 resulted in a well-tolerated C′ dot drug-immune conjugate exhibiting favorable PK, marked reductions in tumor burden, and prolonged survival that yields a clinically promising translational platform for treating HER2 expressing tumors.